New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
04:55 EDTGALE, HUMStocks with implied volatility movement; GAL HUM
Stocks with implied volatility movement; Galena (GAL) 172, Humana (HUM) 39 according to iVolatility
News For GALE;HUM From The Last 14 Days
Check below for free stories on GALE;HUM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
12:27 EDTHUMOn The Fly: Midday Wrap
Subscribe for More Information
10:05 EDTHUMHumana says 'feels good' about how 2015 is 'shaping up'
Sees FY14 3Rs $575M-$775M. Says does not anticipate membership to grow significantly or shrink significantly in the future.
09:55 EDTHUMHumana expects to offer HMO plans in 65 new counties next year
Subscribe for More Information
08:53 EDTHUMHumana expects headwinds this year to include hepatitis C costs
Subscribe for More Information
06:19 EDTHUMHumana sees FY14 Medicaire Advantage membership up 375,000-390,000
Sees FY14 Medicare stand-alone PDPs membership up 575,000-625,000; Sees FY14 State-based Medicaid membership up 225,000-275,000; Sees FY14 Individual commercial membership up 425,000-500,000; Sees FY14 Medicare supplement membership up 20,000-40,000
06:17 EDTHUMHumana backs FY14 EPS $7.25-$7.75, consensus $7.84
Subscribe for More Information
06:16 EDTHUMHumana reports Q2 EPS $2.19, consensus $2.19
Reports Q2 revenue $12.22B, consensus $11.94B; Reports Q2 total premiums and services revenue up 18.6%.
06:07 EDTHUMHumana reports Q2 Total Medical Advantage membership up 14% to 2.8M
Subscribe for More Information
06:07 EDTHUMHumana backs FY14 EPS $7.25-$7.75, consensus $7.84
06:07 EDTHUMHumana reports Q2 EPS $2.19, consensus $2.19
Subscribe for More Information
July 29, 2014
15:53 EDTHUMNotable companies reporting before tomorrow's open
Subscribe for More Information
July 28, 2014
08:17 EDTHUMMCO sell-off provides buying opportunity, says Leerink
Subscribe for More Information
July 25, 2014
10:52 EDTHUMWellCare issues largely company-specific, says UBS
UBS notes that aside from WellCare (WCG), which attributed its lowered guidance to the start-up of its Florida MMA program and other issues, that Centene (CNC), WellPoint (WLP), UnitedHealth (UNH) and Humana (HUM) are the leaders in Medicaid in the state. However, the firm believes a majority of WellCare's issues appear company specific and UBS views any weakness in UnitedHealth, WellPoint, Aetna (AET), or Cigna (CI) as opportunity to buy those four stocks, on all of which it has Buy ratings.
July 24, 2014
06:50 EDTHUMConsumers received $9B in refunds from health insurers, The Hill says
Subscribe for More Information
July 22, 2014
15:46 EDTGALEGalena in-license of Zuplenz makes sense, says Piper Jaffray
Subscribe for More Information
13:46 EDTHUMCourt upholds Obamacare subsidies, NY Times says
Subscribe for More Information
10:43 EDTHUMAppeals court bars subsidies in health care law
A three-judge panel of the D.C. Circuit Court of Appeals struck down part of President Obama's healthcare law by siding today with plaintiffs who argued that the law barred the government from giving subsidies to people in states that chose not to set up their own insurance marketplaces. The appeals court stated, "Because we conclude that the ACA unambiguously restricts the section 36B subsidy to insurance purchased on Exchanges 'established by the State,' we reverse the district court and vacate the IRSís regulation." Twenty-seven states decided against setting up marketplaces, and another nine states partially opted out, according to the Washington Post.
09:55 EDTGALEGalena 'stands little chance' of improving Zuplenz sales, TheStreet says
After Galena BioPharma entered into a license agreement with MonoSol Rx for Zuplenz, TheStreet's Adam Feuerstein predicted that the company "stands little chance of delivering higher sales of Zuplenz than its previous marketer," calling the drug one that "no one wants" and "something to promote while waiting for the phase III study of NeuVax in breast cancer to inevitably fail." Reference Link
07:21 EDTGALEGalena enters into licensing agreement with MonoSol Rx
MonoSol Rx announced that it has licensed Zuplenz to Galena Biopharma. Zuplenz is an oral soluble film, or OSF, for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting. The licensing agreement includes an undisclosed upfront payment from Galena, as well as double digit royalty payments from sales of Zuplenz. Zuplenz is the first oral soluble lingual film product approved by the FDA as a prescription medication, based on MonoSol Rx's proprietary PharmFilm technology.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use